{
  "Metformin First-Line Therapy": [
    {
      "id": "T1-Q01",
      "type": "standard",
      "difficulty": 1,
      "stem": "For most adults with type 2 diabetes who require pharmacotherapy, which agent is recommended as the initial medication?",
      "options": [
        "Sulfonylurea",
        "Metformin",
        "DPP-4 inhibitor",
        "SGLT2 inhibitor"
      ],
      "answer": "B"
    },
    {
      "id": "T1-Q02",
      "type": "standard",
      "difficulty": 1,
      "stem": "What is the usual starting dose strategy for metformin to minimize gastrointestinal side effects?",
      "options": [
        "250–500 mg twice daily with meals, then titrate",
        "Start 1,000 mg twice daily immediately",
        "Once-daily 2,000 mg with breakfast",
        "500 mg at bedtime only, no titration"
      ],
      "answer": "A"
    },
    {
      "id": "T1-Q03",
      "type": "standard",
      "difficulty": 1,
      "stem": "What is the typical target daily dose for metformin beyond which minimal additional glycemic improvement occurs?",
      "options": [
        "2,000 mg/day",
        "3,000 mg/day",
        "1,000 mg/day",
        "1,500 mg/day"
      ],
      "answer": "A"
    },
    {
      "id": "T1-Q04",
      "type": "standard",
      "difficulty": 1,
      "stem": "According to the guideline, metformin should NOT be used in which situation?",
      "options": [
        "Body-mass index > 35 kg/m^2",
        "Estimated GFR < 15 mL/min/1.73 m^2",
        "Age > 75 years",
        "Mild hepatic steatosis only"
      ],
      "answer": "B"
    },
    {
      "id": "T1-Q05",
      "type": "standard",
      "difficulty": 2,
      "stem": "Compared with sulfonylureas, metformin monotherapy is associated with which profile?",
      "options": [
        "Less A1C lowering, more hypoglycemia, weight gain",
        "Greater A1C lowering, higher hypoglycemia risk",
        "Similar A1C lowering, better durability, negligible hypoglycemia, no weight gain",
        "Similar A1C lowering, more weight gain"
      ],
      "answer": "C"
    },
    {
      "id": "T1-Q06",
      "type": "standard",
      "difficulty": 2,
      "stem": "Versus DPP-4 inhibitors, metformin generally provides:",
      "options": [
        "Similar A1C lowering and more weight gain",
        "Less A1C lowering but better tolerability",
        "Better A1C lowering and more weight loss",
        "Greater hypoglycemia risk"
      ],
      "answer": "C"
    },
    {
      "id": "T1-Q07",
      "type": "standard",
      "difficulty": 2,
      "stem": "Typical A1C reduction expected with non‑insulin monotherapy (varies by baseline A1C and agent) is approximately:",
      "options": [
        ">2.5%",
        "0.1% to 0.3%",
        "0.5% to 1.5%",
        "Exactly 1.0%"
      ],
      "answer": "C"
    },
    {
      "id": "T1-Q08",
      "type": "standard",
      "difficulty": 2,
      "stem": "Over what time frame does the maximal effect of a non‑insulin antihyperglycemic monotherapy generally occur?",
      "options": [
        "3–6 months",
        "1–2 weeks",
        "12 months",
        ">18 months"
      ],
      "answer": "A"
    },
    {
      "id": "T1-Q09",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 64‑year‑old with type 2 diabetes and eGFR 22 mL/min/1.73 m^2 is newly diagnosed. Which statement best reflects metformin use?",
      "options": [
        "Metformin can be used with caution because the absolute contraindication is only eGFR < 15",
        "Metformin is absolutely contraindicated because eGFR < 30",
        "Metformin is preferred over insulin in symptomatic hyperglycemia",
        "Metformin must be started at the maximal dose immediately"
      ],
      "answer": "A"
    },
    {
      "id": "T1-Q10",
      "type": "standard",
      "difficulty": 3,
      "stem": "Which UKPDS finding supported metformin in newly diagnosed adults with overweight?",
      "options": [
        "No difference in clinical outcomes",
        "Increased hypoglycemia vs sulfonylureas",
        "Greater weight gain than insulin",
        "Reduced cardiovascular and all‑cause mortality"
      ],
      "answer": "D"
    },
    {
      "id": "T1-Q11",
      "type": "standard",
      "difficulty": 3,
      "stem": "When uptitrating metformin, which approach is recommended to reduce GI adverse effects?",
      "options": [
        "Split dose into fasting-only dosing",
        "Add a sulfonylurea immediately",
        "Slow dose increase over several weeks with meals",
        "Avoid taking with food"
      ],
      "answer": "C"
    },
    {
      "id": "T1-Q12",
      "type": "standard",
      "difficulty": 3,
      "stem": "Which of the following is a recognized absolute contraindication to metformin use per this guideline?",
      "options": [
        "History of lactic acidosis",
        "BMI > 40 kg/m^2",
        "A1C > 10%",
        "Diabetic neuropathy"
      ],
      "answer": "A"
    },
    {
      "id": "T1-Q13",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 55‑year‑old with newly diagnosed type 2 diabetes (A1C 7.9%), no comorbidities, asks about first‑line therapy. What is the most appropriate initial pharmacologic agent?",
      "options": [
        "DPP‑4 inhibitor",
        "Metformin",
        "Basal insulin",
        "Thiazolidinedione"
      ],
      "answer": "B"
    },
    {
      "id": "T1-Q14",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 48‑year‑old started metformin 500 mg BID last week develops mild diarrhea. What is the best next step?",
      "options": [
        "Stop metformin permanently",
        "Switch immediately to insulin",
        "Add a meglitinide",
        "Continue and up‑titrate slowly over weeks"
      ],
      "answer": "D"
    },
    {
      "id": "T1-Q15",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 60‑year‑old with A1C 7.6% on lifestyle alone seeks medication that avoids hypoglycemia and weight gain. Which is most appropriate?",
      "options": [
        "Sulfonylurea",
        "Insulin NPH",
        "Metformin",
        "Meglitinide"
      ],
      "answer": "C"
    },
    {
      "id": "T1-Q16",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 58‑year‑old with eGFR 58 mL/min/1.73 m^2 and no liver disease starts metformin. Which counseling point is most accurate?",
      "options": [
        "Take with meals and titrate gradually",
        "Avoid all carbohydrates",
        "Stop if A1C < 7% after 2 weeks",
        "Increase to >3,000 mg/day for maximal effect"
      ],
      "answer": "A"
    },
    {
      "id": "T1-Q17",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 66‑year‑old with compensated cirrhosis (severe hepatic dysfunction is not documented), eGFR 40, and new A1C 7.8% asks about metformin. Which statement best aligns with the guideline?",
      "options": [
        "Metformin is absolutely contraindicated at eGFR 40",
        "Metformin can be used unless severe hepatic dysfunction or lactic acidosis history exists",
        "Insulin must be used as first‑line regardless of symptoms",
        "Metformin inevitably causes hypoglycemia"
      ],
      "answer": "B"
    },
    {
      "id": "T1-Q18",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 72‑year‑old with eGFR 12 mL/min/1.73 m^2 and prior lactic acidosis presents for diabetes management. Which is the best approach regarding metformin?",
      "options": [
        "Start low‑dose metformin with close monitoring",
        "Avoid metformin due to contraindications",
        "Switch to metformin ER only",
        "Use metformin monotherapy at 2,000 mg/day"
      ],
      "answer": "B"
    },
    {
      "id": "T1-Q19",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 52‑year‑old with new T2D prefers a once‑daily regimen and asks if he can take 2,000 mg metformin all at breakfast from day 1. Best response?",
      "options": [
        "Start 250–500 mg BID with meals and titrate to ~2,000 mg/day",
        "Start 2,000 mg once daily to achieve faster control",
        "Use 1,000 mg BID without meals",
        "Avoid metformin until A1C > 9%"
      ],
      "answer": "A"
    },
    {
      "id": "T1-Q20",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 59‑year‑old with BMI 31 kg/m^2 and A1C 7.5% asks which therapy has shown mortality benefit in newly diagnosed overweight adults. Best answer?",
      "options": [
        "Metformin (UKPDS 34)",
        "Acarbose",
        "Insulin lispro",
        "Meglitinide"
      ],
      "answer": "A"
    }
  ],
  "Immediate Insulin Initiation": [
    {
      "id": "T2-Q01",
      "type": "standard",
      "difficulty": 1,
      "stem": "Insulin should be initiated immediately at diagnosis in which circumstance?",
      "options": [
        "Any A1C > 7% without symptoms",
        "Metabolic decompensation or severe symptomatic hyperglycemia",
        "Any patient age > 65 years",
        "Presence of microalbuminuria alone"
      ],
      "answer": "B"
    },
    {
      "id": "T2-Q02",
      "type": "standard",
      "difficulty": 1,
      "stem": "Which of the following are classic symptoms of severe hyperglycemia that support immediate insulin initiation?",
      "options": [
        "Nausea, vomiting, abdominal pain only",
        "Polyuria, polydipsia, visual blurring",
        "Night sweats and tremor",
        "Bradycardia and hypotension"
      ],
      "answer": "B"
    },
    {
      "id": "T2-Q03",
      "type": "standard",
      "difficulty": 1,
      "stem": "In metabolic decompensation due to hyperglycemia, insulin is recommended with or without which agent?",
      "options": [
        "Sulfonylurea",
        "DPP‑4 inhibitor",
        "Metformin",
        "Meglitinide"
      ],
      "answer": "C"
    },
    {
      "id": "T2-Q04",
      "type": "standard",
      "difficulty": 1,
      "stem": "Once a patient stabilized from metabolic decompensation, what may be possible regarding insulin?",
      "options": [
        "Continue lifelong basal‑bolus regardless",
        "Stop all non‑insulin agents",
        "Taper or discontinue insulin and replace with other agents as required",
        "Switch to sulfonylurea only"
      ],
      "answer": "C"
    },
    {
      "id": "T2-Q05",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which of the following supports initiating insulin even if A1C is unknown?",
      "options": [
        "Hyperosmolar state or ketosis",
        "Mild dyslipidemia",
        "Hypertension alone",
        "Peripheral neuropathy"
      ],
      "answer": "A"
    },
    {
      "id": "T2-Q06",
      "type": "standard",
      "difficulty": 2,
      "stem": "A1C threshold for considering combination therapy at diagnosis (even without metabolic decompensation) is:",
      "options": [
        "> 0.5% above target",
        "> 1.5% above individualized target",
        "> 3% above target",
        "Exactly 8.0%"
      ],
      "answer": "B"
    },
    {
      "id": "T2-Q07",
      "type": "standard",
      "difficulty": 2,
      "stem": "In severe symptomatic hyperglycemia, which initial pharmacologic approach is recommended?",
      "options": [
        "Start a DPP‑4 inhibitor only",
        "Delay therapy and recheck A1C in 3 months",
        "Start a thiazolidinedione only",
        "Start insulin promptly (± metformin)"
      ],
      "answer": "D"
    },
    {
      "id": "T2-Q08",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which feature suggests unintentional weight loss related to hyperglycemia and supports immediate insulin?",
      "options": [
        "Stable weight for 1 year",
        "Weight gain after diet change",
        "Catabolic weight loss over weeks to months",
        "Fluid retention"
      ],
      "answer": "C"
    },
    {
      "id": "T2-Q09",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 45‑year‑old presents with polyuria, polydipsia, and blurry vision. Random glucose 28 mmol/L with ketonuria. Best initial step?",
      "options": [
        "Start metformin alone",
        "Begin GLP‑1 RA monotherapy",
        "Initiate insulin therapy (± metformin)",
        "Delay treatment pending A1C"
      ],
      "answer": "C"
    },
    {
      "id": "T2-Q10",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 58‑year‑old with new T2D, A1C 11.8%, 7‑kg unintentional weight loss, and serum osmolality high. Best initial pharmacotherapy?",
      "options": [
        "Metformin only",
        "SGLT2 inhibitor only",
        "Sulfonylurea",
        "Insulin"
      ],
      "answer": "D"
    },
    {
      "id": "T2-Q11",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 63‑year‑old with symptomatic hyperglycemia starts insulin. After stabilization, A1C falls to target on metformin + GLP‑1 RA. What can be done with insulin?",
      "options": [
        "Continue full basal‑bolus indefinitely",
        "Switch to TZD monotherapy",
        "Taper or discontinue if appropriate",
        "Stop all non‑insulin agents"
      ],
      "answer": "C"
    },
    {
      "id": "T2-Q12",
      "type": "standard",
      "difficulty": 3,
      "stem": "Which of the following *alone* does NOT constitute an indication for immediate insulin per the guideline?",
      "options": [
        "Hyperosmolar state",
        "Ketonuria",
        "Microalbuminuria without symptoms",
        "Severe symptomatic hyperglycemia"
      ],
      "answer": "C"
    },
    {
      "id": "T2-Q13",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 50‑year‑old with fasting glucose 17 mmol/L, polyuria, polydipsia, and 5‑kg weight loss is diagnosed with T2D. Best initial pharmacotherapy?",
      "options": [
        "Metformin only",
        "Insulin (± metformin)",
        "DPP‑4 inhibitor",
        "Thiazolidinedione"
      ],
      "answer": "B"
    },
    {
      "id": "T2-Q14",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 61‑year‑old presents with blurry vision and random glucose 27 mmol/L with positive serum ketones. What is the most appropriate immediate management?",
      "options": [
        "Start SGLT2 inhibitor",
        "Start acarbose",
        "Reassure and repeat labs in 1 month",
        "Start insulin therapy"
      ],
      "answer": "D"
    },
    {
      "id": "T2-Q15",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 54‑year‑old has A1C 9.2% without symptoms or catabolism. Which initial approach is preferred?",
      "options": [
        "Immediate insulin",
        "No pharmacotherapy; lifestyle only",
        "Combination non‑insulin therapy at diagnosis",
        "DPP‑4 inhibitor monotherapy"
      ],
      "answer": "C"
    },
    {
      "id": "T2-Q16",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 67‑year‑old with severe symptomatic hyperglycemia begins insulin. Two months later, symptoms resolve and A1C 7.3% on metformin + SGLT2 inhibitor. Next step?",
      "options": [
        "Consider tapering insulin",
        "Stop all non‑insulin agents",
        "Increase insulin dose empirically",
        "Add sulfonylurea"
      ],
      "answer": "A"
    },
    {
      "id": "T2-Q17",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 43‑year‑old with random glucose 30 mmol/L, elevated serum osmolality, and confusion is diagnosed with T2D. Best initial pharmacologic choice?",
      "options": [
        "Insulin",
        "Metformin",
        "GLP‑1 RA",
        "Sulfonylurea"
      ],
      "answer": "A"
    },
    {
      "id": "T2-Q18",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 59‑year‑old with BMI 29 kg/m^2, polyuria, and A1C 10.8% starts insulin. After stabilization, which statement best reflects guideline‑concordant care?",
      "options": [
        "Insulin must be lifelong regardless of response",
        "Other antihyperglycemic agents may replace insulin if targets are maintained",
        "Secretagogues should always be added",
        "DPP‑4 inhibitors are contraindicated after insulin"
      ],
      "answer": "B"
    },
    {
      "id": "T2-Q19",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 72‑year‑old with A1C 8.2% reports mild fatigue but no polyuria/polydipsia, no ketones, and stable weight. Which initial strategy is most appropriate?",
      "options": [
        "Immediate insulin due to age",
        "Non‑insulin therapy; insulin not mandatory",
        "No therapy is needed",
        "Insulin plus full bolus immediately"
      ],
      "answer": "B"
    },
    {
      "id": "T2-Q20",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 58‑year‑old with severe symptomatic hyperglycemia asks if metformin alone is sufficient initially. Best response?",
      "options": [
        "Metformin alone is sufficient",
        "Any oral agent is fine",
        "Start GLP‑1 RA alone",
        "Insulin should be initiated promptly; metformin may be added"
      ],
      "answer": "D"
    }
  ],
  "Combination Therapy at Diagnosis": [
    {
      "id": "T3-Q01",
      "type": "standard",
      "difficulty": 1,
      "stem": "At diagnosis, combination therapy should be considered when A1C is:",
      "options": [
        "> 1.5% above individualized target",
        "> 0.5% above target",
        "> 3% above target",
        "Exactly 8.0%"
      ],
      "answer": "A"
    },
    {
      "id": "T3-Q02",
      "type": "standard",
      "difficulty": 1,
      "stem": "Combining two oral agents at submaximal doses versus pushing one to the maximum tends to result in:",
      "options": [
        "More hypoglycemia",
        "Worse adherence",
        "Fewer side effects",
        "No difference"
      ],
      "answer": "C"
    },
    {
      "id": "T3-Q03",
      "type": "standard",
      "difficulty": 1,
      "stem": "Compared with metformin alone, initial combination therapy lowers average A1C by approximately:",
      "options": [
        "Exactly 2.5% more",
        "0.4% to 1.0% more",
        "No additional reduction",
        ">1.5% more"
      ],
      "answer": "B"
    },
    {
      "id": "T3-Q04",
      "type": "standard",
      "difficulty": 1,
      "stem": "Initial combination therapy increases the likelihood of achieving A1C < 7% at 6 months by roughly:",
      "options": [
        "10%",
        "40%",
        "75%",
        "5%"
      ],
      "answer": "B"
    },
    {
      "id": "T3-Q05",
      "type": "standard",
      "difficulty": 2,
      "stem": "When selecting the second agent to add to metformin, choices should be based primarily on:",
      "options": [
        "Individual priorities, preferences, and comorbidities",
        "Cost alone",
        "Provider preference only",
        "Random selection to avoid bias"
      ],
      "answer": "A"
    },
    {
      "id": "T3-Q06",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which factor most affects the A1C‑lowering efficacy of SGLT2 inhibitors?",
      "options": [
        "Patient age",
        "eGFR level (declines with lower eGFR)",
        "Sex",
        "Time of day administered"
      ],
      "answer": "B"
    },
    {
      "id": "T3-Q07",
      "type": "standard",
      "difficulty": 2,
      "stem": "Non‑insulin monotherapy typically achieves maximal glycemic effect within:",
      "options": [
        "1–2 weeks",
        "3–6 months",
        "12 months",
        ">18 months"
      ],
      "answer": "B"
    },
    {
      "id": "T3-Q08",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which combination is generally NOT recommended due to similar mechanisms?",
      "options": [
        "Sulfonylurea + meglitinide",
        "Metformin + SGLT2 inhibitor",
        "Metformin + GLP‑1 RA",
        "Metformin + DPP‑4 inhibitor"
      ],
      "answer": "A"
    },
    {
      "id": "T3-Q09",
      "type": "standard",
      "difficulty": 3,
      "stem": "A patient with A1C 9.0% at diagnosis (target 7.0%) asks about speed of control. Which strategy aligns with the guideline?",
      "options": [
        "Start metformin alone and reassess in 12 months",
        "Start insulin immediately in all such cases",
        "Start dual therapy to achieve faster and greater A1C reduction",
        "Delay therapy 3 months"
      ],
      "answer": "C"
    },
    {
      "id": "T3-Q10",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 62‑year‑old with A1C 8.8% and eGFR 48 mL/min/1.73 m^2 wants weight loss. Which add‑on to metformin is most consistent with those goals?",
      "options": [
        "GLP‑1 RA",
        "Sulfonylurea",
        "Thiazolidinedione",
        "Meglitinide"
      ],
      "answer": "A"
    },
    {
      "id": "T3-Q11",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 70‑year‑old with A1C 8.7% (target 7%), asymptomatic, prefers to minimize hypoglycemia. Which add‑on class is preferable?",
      "options": [
        "Sulfonylurea",
        "Insulin",
        "SGLT2 inhibitor",
        "Meglitinide"
      ],
      "answer": "C"
    },
    {
      "id": "T3-Q12",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 58‑year‑old with A1C 8.6% (target 7%) has limited insurance coverage. Which lower‑cost option may be considered?",
      "options": [
        "GLP‑1 RA",
        "Sulfonylurea",
        "SGLT2 inhibitor",
        "DPP‑4 inhibitor"
      ],
      "answer": "B"
    },
    {
      "id": "T3-Q13",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 55‑year‑old newly diagnosed with A1C 9.1% (target 7%), eGFR 85, no comorbidities. What is the preferred initial pharmacotherapy?",
      "options": [
        "Metformin alone",
        "Metformin + a second agent",
        "Insulin only",
        "No pharmacotherapy"
      ],
      "answer": "B"
    },
    {
      "id": "T3-Q14",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 63‑year‑old with A1C 8.9% and desire for weight loss asks which combo with metformin is likely to help weight. Best answer?",
      "options": [
        "GLP‑1 RA or SGLT2 inhibitor",
        "Sulfonylurea or insulin",
        "Thiazolidinedione",
        "Meglitinide"
      ],
      "answer": "A"
    },
    {
      "id": "T3-Q15",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 49‑year‑old with A1C 9.2% (target 7%) prefers to avoid hypoglycemia. Which add‑on class is most consistent?",
      "options": [
        "SGLT2 inhibitor",
        "Sulfonylurea",
        "Insulin",
        "Meglitinide"
      ],
      "answer": "A"
    },
    {
      "id": "T3-Q16",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 61‑year‑old with eGFR 38 mL/min/1.73 m^2 is considering an SGLT2 inhibitor as add‑on to metformin. Which statement is true?",
      "options": [
        "Efficacy is independent of eGFR",
        "Glycemic efficacy declines as eGFR decreases",
        "Contraindicated at any eGFR",
        "Causes immediate hypoglycemia"
      ],
      "answer": "B"
    },
    {
      "id": "T3-Q17",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 70‑year‑old with A1C 9.0% and limited budget asks for an affordable add‑on to metformin. Which is most cost‑effective?",
      "options": [
        "GLP‑1 RA",
        "Sulfonylurea",
        "SGLT2 inhibitor",
        "DPP‑4 inhibitor"
      ],
      "answer": "B"
    },
    {
      "id": "T3-Q18",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 52‑year‑old with A1C 8.8% (target 7%) and symptomatic hypotension wants to avoid agents with diuretic effect. Which add‑on is preferable?",
      "options": [
        "SGLT2 inhibitor",
        "High‑dose metformin immediately",
        "Insulin",
        "GLP‑1 RA"
      ],
      "answer": "D"
    },
    {
      "id": "T3-Q19",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 58‑year‑old with A1C 8.7% has frequent late meals and asks about hypoglycemia risk with add‑on. Which class has negligible hypoglycemia risk as monotherapy?",
      "options": [
        "Sulfonylurea",
        "Insulin",
        "Meglitinide",
        "GLP‑1 RA"
      ],
      "answer": "D"
    },
    {
      "id": "T3-Q20",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 60‑year‑old with A1C 9.1% and BMI 29 kg/m^2 asks whether triple oral therapy up front is required. Guideline‑concordant answer?",
      "options": [
        "Triple therapy is required at diagnosis",
        "Start dual therapy; more agents can be added stepwise if needed",
        "Insulin must be started immediately",
        "Delay therapy 6 months"
      ],
      "answer": "B"
    }
  ],
  "SGLT2i and GLP-1 RA Cardiorenal Protection": [
    {
      "id": "T4-Q01",
      "type": "standard",
      "difficulty": 1,
      "stem": "For people with type 2 diabetes at high cardiovascular risk, which GLP‑1 RAs have demonstrated MACE reduction?",
      "options": [
        "Dulaglutide, liraglutide, subcutaneous semaglutide",
        "Lixisenatide, oral semaglutide",
        "Exenatide once‑weekly only",
        "Albiglutide"
      ],
      "answer": "A"
    },
    {
      "id": "T4-Q02",
      "type": "standard",
      "difficulty": 1,
      "stem": "Which SGLT2 inhibitors demonstrated MACE reduction in high CV risk populations?",
      "options": [
        "Empagliflozin and canagliflozin",
        "Dapagliflozin and ertugliflozin",
        "All SGLT2 inhibitors equally",
        "None"
      ],
      "answer": "A"
    },
    {
      "id": "T4-Q03",
      "type": "standard",
      "difficulty": 1,
      "stem": "For individuals with heart failure (reduced or preserved EF), which SGLT2 inhibitors have proven benefit?",
      "options": [
        "Canagliflozin and ertugliflozin",
        "Dapagliflozin and empagliflozin",
        "Only dapagliflozin",
        "None"
      ],
      "answer": "B"
    },
    {
      "id": "T4-Q04",
      "type": "standard",
      "difficulty": 1,
      "stem": "For chronic kidney disease, which SGLT2 inhibitors have demonstrated renal outcome benefit?",
      "options": [
        "Ertugliflozin only",
        "Canagliflozin, dapagliflozin, empagliflozin",
        "Empagliflozin only",
        "No SGLT2 inhibitor"
      ],
      "answer": "B"
    },
    {
      "id": "T4-Q05",
      "type": "standard",
      "difficulty": 2,
      "stem": "When should SGLT2 inhibitors or GLP‑1 RAs for cardiorenal protection be started in eligible individuals?",
      "options": [
        "Only after 3 oral agents fail",
        "At diagnosis when comorbidities are present, even if A1C is at target",
        "Only if A1C > 9%",
        "Only after insulin"
      ],
      "answer": "B"
    },
    {
      "id": "T4-Q06",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which of the following GLP‑1 RA agents lacks clear evidence for cardiorenal outcome benefits in CVOTs?",
      "options": [
        "Lixisenatide",
        "Liraglutide",
        "Dulaglutide",
        "Subcutaneous semaglutide"
      ],
      "answer": "A"
    },
    {
      "id": "T4-Q07",
      "type": "standard",
      "difficulty": 2,
      "stem": "Beyond MACE, SGLT2 inhibitors consistently reduce which outcomes across trials in high CV risk populations?",
      "options": [
        "Diabetic retinopathy progression only",
        "Amputation risk across all agents",
        "Heart failure events and renal outcomes",
        "Hypoglycemia"
      ],
      "answer": "C"
    },
    {
      "id": "T4-Q08",
      "type": "standard",
      "difficulty": 2,
      "stem": "In trials of SGLT2 inhibitors for heart failure, what proportion roughly did NOT have diabetes?",
      "options": [
        "None",
        "About half",
        "All participants had diabetes",
        "<5%"
      ],
      "answer": "B"
    },
    {
      "id": "T4-Q09",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 62‑year‑old with T2D and established ASCVD asks which GLP‑1 RA reduces MACE. Best choice?",
      "options": [
        "Lixisenatide",
        "Oral semaglutide",
        "Liraglutide",
        "Exenatide once‑weekly"
      ],
      "answer": "C"
    },
    {
      "id": "T4-Q10",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 70‑year‑old with HFpEF and T2D seeks therapy with proven HF benefit. Which is recommended?",
      "options": [
        "Dapagliflozin or empagliflozin",
        "Liraglutide",
        "Acarbose",
        "Meglitinide"
      ],
      "answer": "A"
    },
    {
      "id": "T4-Q11",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 65‑year‑old with CKD (eGFR 35) and T2D asks about renal protection. Which option is evidence‑based?",
      "options": [
        "Start an SGLT2 inhibitor with proven renal benefit",
        "GLP‑1 RA is the only option",
        "SGLT2 inhibitors are contraindicated in CKD",
        "Use DPP‑4 inhibitor for renal protection"
      ],
      "answer": "A"
    },
    {
      "id": "T4-Q12",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 58‑year‑old with established ASCVD but no HF or CKD asks which SGLT2 inhibitor has MACE reduction evidence. Best answer?",
      "options": [
        "Dapagliflozin and ertugliflozin",
        "Empagliflozin (Grade A) and canagliflozin (Grade B)",
        "No SGLT2 inhibitor has MACE data",
        "All SGLT2 inhibitors equally reduce MACE"
      ],
      "answer": "B"
    },
    {
      "id": "T4-Q13",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 59‑year‑old with T2D, prior MI, and A1C 7.0% on metformin asks about additional therapy for CV protection. Best option?",
      "options": [
        "No additional therapy since A1C is at target",
        "Add sulfonylurea for CV benefit",
        "Add a GLP‑1 RA (e.g., liraglutide) or an SGLT2 inhibitor with proven CV benefit",
        "Switch to insulin"
      ],
      "answer": "C"
    },
    {
      "id": "T4-Q14",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 68‑year‑old with T2D and HF with reduced EF wants fewer hospitalizations. Which medication class has proven benefit regardless of diabetes status?",
      "options": [
        "DPP‑4 inhibitor",
        "Acarbose",
        "SGLT2 inhibitor (dapagliflozin or empagliflozin)",
        "Meglitinide"
      ],
      "answer": "C"
    },
    {
      "id": "T4-Q15",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 72‑year‑old with T2D and CKD (eGFR 42) asks about kidney protection. Which is most appropriate?",
      "options": [
        "Initiate an SGLT2 inhibitor with renal outcome data",
        "Avoid all SGLT2 inhibitors",
        "Start only GLP‑1 RA for renal protection",
        "Use sulfonylurea for renoprotection"
      ],
      "answer": "A"
    },
    {
      "id": "T4-Q16",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 63‑year‑old with ASCVD but no HF/CKD prefers weekly injections. Which GLP‑1 RA reduces MACE and fits preference?",
      "options": [
        "Dulaglutide",
        "Lixisenatide",
        "Exenatide QW",
        "Oral semaglutide"
      ],
      "answer": "A"
    },
    {
      "id": "T4-Q17",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 66‑year‑old with T2D, HFpEF, and eGFR 50 is on metformin. A1C 6.8%. Best addition primarily for HF benefit?",
      "options": [
        "Liraglutide",
        "Empagliflozin",
        "Sitagliptin",
        "Nateglinide"
      ],
      "answer": "B"
    },
    {
      "id": "T4-Q18",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 60‑year‑old with T2D and prior stroke asks for an agent with demonstrated MACE reduction among GLP‑1 RAs. Best choice?",
      "options": [
        "Lixisenatide",
        "Oral semaglutide",
        "Exenatide once‑weekly",
        "Subcutaneous semaglutide"
      ],
      "answer": "D"
    },
    {
      "id": "T4-Q19",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 71‑year‑old with CKD (eGFR 38) and macroalbuminuria asks which SGLT2 inhibitor class evidence supports. Best counseling?",
      "options": [
        "Only ertugliflozin has renal data",
        "SGLT2 inhibitors worsen renal outcomes",
        "No benefits without diabetes",
        "Canagliflozin, dapagliflozin, or empagliflozin reduce renal/CV composite outcomes"
      ],
      "answer": "D"
    },
    {
      "id": "T4-Q20",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 65‑year‑old with T2D and multiple CV risk factors (no established ASCVD) asks about MACE prevention with SGLT2 inhibitors. Best statement?",
      "options": [
        "Strong MACE reduction in risk‑factor‑only cohorts across agents",
        "No CV benefits even with ASCVD",
        "Benefits are clear in established ASCVD; evidence in risk factors alone is less certain",
        "GLP‑1 RAs have no MACE data"
      ],
      "answer": "C"
    }
  ],
  "Treatment Intensification": [
    {
      "id": "T5-Q01",
      "type": "standard",
      "difficulty": 1,
      "stem": "Dose adjustments, substitutions, or additions should aim to reach target A1C within:",
      "options": [
        "1–2 weeks",
        "3–6 months",
        "12 months",
        "At the provider’s convenience"
      ],
      "answer": "B"
    },
    {
      "id": "T5-Q02",
      "type": "standard",
      "difficulty": 1,
      "stem": "Cardiovascular and renal status should be reviewed at least:",
      "options": [
        "Annually",
        "Monthly",
        "Every 5 years",
        "Only at diagnosis"
      ],
      "answer": "A"
    },
    {
      "id": "T5-Q03",
      "type": "standard",
      "difficulty": 1,
      "stem": "Before intensifying therapy for rising A1C, which assessment is recommended?",
      "options": [
        "Check for precipitating factors (infection, ischemia), adherence, costs, preferences",
        "Skip assessments and increase dose",
        "Stop all current agents",
        "Refer to surgery"
      ],
      "answer": "A"
    },
    {
      "id": "T5-Q04",
      "type": "standard",
      "difficulty": 1,
      "stem": "When new agents are added, existing glucose‑lowering meds should generally be:",
      "options": [
        "Stopped immediately",
        "Switched to insulin only",
        "Given at maximal doses always",
        "Continued unless contraindicated"
      ],
      "answer": "D"
    },
    {
      "id": "T5-Q05",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which combination is NOT recommended due to overlapping mechanism?",
      "options": [
        "Metformin with SGLT2 inhibitor",
        "Metformin with GLP‑1 RA",
        "DPP‑4 inhibitor with GLP‑1 RA",
        "Metformin with DPP‑4 inhibitor"
      ],
      "answer": "C"
    },
    {
      "id": "T5-Q06",
      "type": "standard",
      "difficulty": 2,
      "stem": "When selecting add‑on therapy for intensification, which factor is LEAST aligned with the guideline’s person‑centred approach?",
      "options": [
        "Need/desire for weight loss",
        "Prescriber habit without patient input",
        "Risk and importance of avoiding hypoglycemia",
        "Comorbidities and insurance coverage"
      ],
      "answer": "B"
    },
    {
      "id": "T5-Q07",
      "type": "standard",
      "difficulty": 2,
      "stem": "Beta‑cell decline over time in type 2 diabetes primarily implies:",
      "options": [
        "Immediate insulin for all",
        "Need for stepwise therapy intensification",
        "Diet alone will suffice",
        "Oral agents become completely ineffective in all"
      ],
      "answer": "B"
    },
    {
      "id": "T5-Q08",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which is a reasonable intensification goal after a change?",
      "options": [
        "Achieve normoglycemia in 1 week",
        "Reduce A1C by 3% in 2 weeks",
        "Stop all non‑insulin agents",
        "Achieve individualized A1C within 3–6 months"
      ],
      "answer": "D"
    },
    {
      "id": "T5-Q09",
      "type": "standard",
      "difficulty": 3,
      "stem": "A patient’s A1C rose from 7.2% to 8.3% in 4 months on metformin. He reports a recent infection and prednisone course. First step?",
      "options": [
        "Add bolus insulin immediately",
        "Stop metformin",
        "Switch to sulfonylurea only",
        "Address reversible precipitants and reassess"
      ],
      "answer": "D"
    },
    {
      "id": "T5-Q10",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 69‑year‑old prioritizes weight loss and avoiding hypoglycemia. Which intensification choice fits best?",
      "options": [
        "GLP‑1 RA or SGLT2 inhibitor",
        "Sulfonylurea",
        "High‑dose insulin",
        "Meglitinide"
      ],
      "answer": "A"
    },
    {
      "id": "T5-Q11",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 61‑year‑old with A1C 8.4% on metformin + DPP‑4 inhibitor wants stronger effect without weight gain. Best next step?",
      "options": [
        "Add sulfonylurea",
        "Add SGLT2 inhibitor or switch DPP‑4 to GLP‑1 RA",
        "Stop all agents",
        "Start thiazolidinedione always"
      ],
      "answer": "B"
    },
    {
      "id": "T5-Q12",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 58‑year‑old with limited insurance cannot afford GLP‑1 RA/SGLT2i. Which intensification is the lowest‑cost?",
      "options": [
        "DPP‑4 inhibitor",
        "Insulin degludec",
        "Sulfonylurea",
        "Acarbose"
      ],
      "answer": "C"
    },
    {
      "id": "T5-Q13",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 60‑year‑old with A1C 8.5% on metformin admits poor adherence due to GI upset and costs. First step?",
      "options": [
        "Add insulin immediately",
        "Address side effects/cost barriers before changing regimen",
        "Switch to TZD without discussion",
        "Stop all meds"
      ],
      "answer": "B"
    },
    {
      "id": "T5-Q14",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 55‑year‑old’s A1C rose after a prolonged infection. After recovery, A1C is 7.6% on same regimen. What does this indicate?",
      "options": [
        "Transient precipitant resolved; continue to monitor",
        "Permanent therapy failure",
        "Need for immediate insulin",
        "Metformin is contraindicated"
      ],
      "answer": "A"
    },
    {
      "id": "T5-Q15",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 72‑year‑old with mild CKD and high hypoglycemia fear seeks intensification. Which class is best avoided due to higher hypoglycemia risk?",
      "options": [
        "GLP‑1 RA",
        "SGLT2 inhibitor",
        "Sulfonylurea",
        "DPP‑4 inhibitor"
      ],
      "answer": "C"
    },
    {
      "id": "T5-Q16",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 68‑year‑old with A1C 8.9% prioritizes weight loss. Which intensification aligns with this goal?",
      "options": [
        "Thiazolidinedione",
        "GLP‑1 RA (or consider SGLT2 inhibitor)",
        "Sulfonylurea",
        "Increase basal insulin without limit"
      ],
      "answer": "B"
    },
    {
      "id": "T5-Q17",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 64‑year‑old with A1C 8.4% on metformin + sulfonylurea has frequent hypoglycemia. Preferred intensification path?",
      "options": [
        "Increase sulfonylurea dose",
        "Add meglitinide",
        "Add basal‑bolus insulin immediately",
        "Switch/augment with GLP‑1 RA or SGLT2 inhibitor"
      ],
      "answer": "D"
    },
    {
      "id": "T5-Q18",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 59‑year‑old with obesity, OSA, and osteoarthritis wants fewer injections and weight loss. Best intensification?",
      "options": [
        "Premixed insulin",
        "Acarbose",
        "Meglitinide",
        "Once‑weekly GLP‑1 RA"
      ],
      "answer": "D"
    },
    {
      "id": "T5-Q19",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 70‑year‑old on metformin + GLP‑1 RA still above target and has CKD with albuminuria. Next step?",
      "options": [
        "Add sulfonylurea first",
        "Stop GLP‑1 RA",
        "Add an SGLT2 inhibitor with renal benefit if eGFR allows",
        "No further options"
      ],
      "answer": "C"
    },
    {
      "id": "T5-Q20",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 63‑year‑old A1C 8.2% after 4 months of dual therapy asks if the regimen failed. Best response?",
      "options": [
        "Targets should be met within 3–6 months; consider adjusting now",
        "Wait 12 months before intensifying",
        "Therapy cannot be intensified further",
        "Stop all meds and retry lifestyle only"
      ],
      "answer": "A"
    }
  ],
  "Comparative Drug Class Efficacy/Safety": [
    {
      "id": "T6-Q01",
      "type": "standard",
      "difficulty": 1,
      "stem": "Which classes have lower hypoglycemia risk compared with sulfonylureas and insulin?",
      "options": [
        "Incretins (GLP‑1 RA/DPP‑4), SGLT2 inhibitors, thiazolidinediones",
        "Sulfonylureas and insulin",
        "Meglitinides and insulin",
        "Acarbose and sulfonylureas"
      ],
      "answer": "A"
    },
    {
      "id": "T6-Q02",
      "type": "standard",
      "difficulty": 1,
      "stem": "Which classes are associated with weight loss?",
      "options": [
        "GLP‑1 RAs/GIP‑GLP‑1 RAs and SGLT2 inhibitors",
        "DPP‑4 inhibitors and TZDs",
        "Sulfonylureas and insulin",
        "Acarbose and TZDs"
      ],
      "answer": "A"
    },
    {
      "id": "T6-Q03",
      "type": "standard",
      "difficulty": 1,
      "stem": "Which agents are associated with the most weight gain?",
      "options": [
        "DPP‑4 inhibitors",
        "GLP‑1 RAs",
        "SGLT2 inhibitors",
        "Insulin, sulfonylureas, thiazolidinediones"
      ],
      "answer": "D"
    },
    {
      "id": "T6-Q04",
      "type": "standard",
      "difficulty": 1,
      "stem": "Which class has a neutral effect on weight?",
      "options": [
        "GLP‑1 RAs",
        "DPP‑4 inhibitors",
        "Insulin",
        "Sulfonylureas"
      ],
      "answer": "B"
    },
    {
      "id": "T6-Q05",
      "type": "standard",
      "difficulty": 2,
      "stem": "SGLT2 inhibitor glycemic efficacy is reduced primarily by:",
      "options": [
        "Older age",
        "Declining eGFR",
        "Female sex",
        "Evening dosing"
      ],
      "answer": "B"
    },
    {
      "id": "T6-Q06",
      "type": "standard",
      "difficulty": 2,
      "stem": "Insulin has the greatest potential for A1C lowering because:",
      "options": [
        "It is always weight neutral",
        "It prevents beta‑cell decline",
        "It has no dose ceiling (limited by hypoglycemia)",
        "It is combined only with sulfonylureas"
      ],
      "answer": "C"
    },
    {
      "id": "T6-Q07",
      "type": "standard",
      "difficulty": 2,
      "stem": "Compared with sulfonylureas, DPP‑4 inhibitors as add‑on to metformin demonstrate:",
      "options": [
        "Greater weight gain",
        "More hypoglycemia",
        "Lower hypoglycemia risk and weight neutrality",
        "No difference in safety"
      ],
      "answer": "C"
    },
    {
      "id": "T6-Q08",
      "type": "standard",
      "difficulty": 2,
      "stem": "Typical magnitude of weight gain seen with insulin, sulfonylureas, or TZDs in trials is approximately:",
      "options": [
        "<0.5 kg",
        "~1.5–5.0 kg",
        ">10 kg",
        "No weight change"
      ],
      "answer": "B"
    },
    {
      "id": "T6-Q09",
      "type": "standard",
      "difficulty": 3,
      "stem": "Which pairing is most accurate regarding weight effect?",
      "options": [
        "GLP‑1 RA → weight loss; DPP‑4 inhibitor → weight neutral",
        "DPP‑4 inhibitor → weight loss; SGLT2 → weight gain",
        "Sulfonylurea → weight neutral",
        "Insulin → weight loss"
      ],
      "answer": "A"
    },
    {
      "id": "T6-Q10",
      "type": "standard",
      "difficulty": 3,
      "stem": "Which class selection best minimizes hypoglycemia when added to metformin?",
      "options": [
        "GLP‑1 RA or SGLT2 inhibitor",
        "Sulfonylurea",
        "High‑dose insulin",
        "Meglitinide"
      ],
      "answer": "A"
    },
    {
      "id": "T6-Q11",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 64‑year‑old wants an oral agent with weight loss. Which is preferred?",
      "options": [
        "DPP‑4 inhibitor",
        "SGLT2 inhibitor",
        "TZD",
        "Sulfonylurea"
      ],
      "answer": "B"
    },
    {
      "id": "T6-Q12",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 58‑year‑old with eGFR 35 mL/min/1.73 m^2 asks about SGLT2 inhibitor glycemic effect. Best response?",
      "options": [
        "Glycemic effect declines as eGFR falls",
        "Efficacy increases with lower eGFR",
        "Independent of kidney function",
        "Causes immediate hypoglycemia"
      ],
      "answer": "A"
    },
    {
      "id": "T6-Q13",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 70‑year‑old on metformin seeks an add‑on with low hypoglycemia risk and potential weight loss. Best option?",
      "options": [
        "Sulfonylurea",
        "Insulin",
        "Meglitinide",
        "GLP‑1 RA or SGLT2 inhibitor"
      ],
      "answer": "D"
    },
    {
      "id": "T6-Q14",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 59‑year‑old needs add‑on therapy but wants to avoid weight gain. Which class is weight neutral?",
      "options": [
        "Sulfonylurea",
        "TZD",
        "Insulin",
        "DPP‑4 inhibitor"
      ],
      "answer": "D"
    },
    {
      "id": "T6-Q15",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 66‑year‑old with A1C 8.1% and nocturnal hypoglycemia on sulfonylurea asks about alternatives. Best suggestion?",
      "options": [
        "Increase sulfonylurea dose",
        "Switch to GLP‑1 RA or SGLT2 inhibitor",
        "Add meglitinide",
        "Continue current regimen"
      ],
      "answer": "B"
    },
    {
      "id": "T6-Q16",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 62‑year‑old has edema and weight gain on TZD. Which alternative class avoids weight gain?",
      "options": [
        "Sulfonylurea",
        "SGLT2 inhibitor",
        "Insulin",
        "Meglitinide"
      ],
      "answer": "B"
    },
    {
      "id": "T6-Q17",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 55‑year‑old with eGFR 40 prefers oral agents and weight loss. Which counseling is accurate?",
      "options": [
        "SGLT2 inhibitors promote weight loss but glycemic efficacy declines with lower eGFR",
        "SGLT2 efficacy improves as eGFR falls",
        "DPP‑4 inhibitors cause consistent weight loss",
        "Sulfonylureas are weight neutral"
      ],
      "answer": "A"
    },
    {
      "id": "T6-Q18",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 68‑year‑old with frequent hypoglycemia on insulin seeks to reduce episodes while maintaining control. Which non‑insulin add‑on is reasonable?",
      "options": [
        "Higher sulfonylurea dose",
        "GLP‑1 RA",
        "Meglitinide",
        "Switch to acarbose"
      ],
      "answer": "B"
    },
    {
      "id": "T6-Q19",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 60‑year‑old asks which class offers greatest A1C reduction potential overall. Best answer?",
      "options": [
        "DPP‑4 inhibitors",
        "Acarbose",
        "Meglitinides",
        "Insulin (limited by hypoglycemia)"
      ],
      "answer": "D"
    },
    {
      "id": "T6-Q20",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 72‑year‑old on metformin wants weight loss and CV benefit. Which add‑on best fits both?",
      "options": [
        "Sulfonylurea",
        "GLP‑1 RA",
        "TZD",
        "Acarbose"
      ],
      "answer": "B"
    }
  ],
  "Cardiorenal Outcome Evidence (Trials)": [
    {
      "id": "T7-Q01",
      "type": "standard",
      "difficulty": 1,
      "stem": "Which trial demonstrated MACE reduction with liraglutide?",
      "options": [
        "ELIXA",
        "LEADER",
        "EXSCEL",
        "PIONEER‑6"
      ],
      "answer": "B"
    },
    {
      "id": "T7-Q02",
      "type": "standard",
      "difficulty": 1,
      "stem": "Which trial showed MACE reduction with subcutaneous semaglutide?",
      "options": [
        "PIONEER‑6",
        "SUSTAIN‑6",
        "ELIXA",
        "EXSCEL"
      ],
      "answer": "B"
    },
    {
      "id": "T7-Q03",
      "type": "standard",
      "difficulty": 1,
      "stem": "Which SGLT2 CVOT first demonstrated significant CV and mortality benefits in T2D with established CVD?",
      "options": [
        "DECLARE‑TIMI 58",
        "VERTIS‑CV",
        "EMPA‑REG OUTCOME",
        "CANVAS‑R"
      ],
      "answer": "C"
    },
    {
      "id": "T7-Q04",
      "type": "standard",
      "difficulty": 1,
      "stem": "Which trial program showed canagliflozin reduced MACE?",
      "options": [
        "VERTIS‑CV",
        "DECLARE‑TIMI 58",
        "CANVAS Program",
        "DAPA‑HF"
      ],
      "answer": "C"
    },
    {
      "id": "T7-Q05",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which GLP‑1 RA agent did NOT demonstrate clear cardiorenal outcome benefits in its CVOT?",
      "options": [
        "Liraglutide (LEADER)",
        "Lixisenatide (ELIXA)",
        "Dulaglutide (REWIND)",
        "Subcutaneous semaglutide (SUSTAIN‑6)"
      ],
      "answer": "B"
    },
    {
      "id": "T7-Q06",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which SGLT2 inhibitor trial did NOT show a statistically significant MACE reduction, despite other benefits?",
      "options": [
        "EMPA‑REG OUTCOME (empagliflozin)",
        "DECLARE‑TIMI 58 (dapagliflozin)",
        "CANVAS (canagliflozin)",
        "CANVAS‑R (canagliflozin)"
      ],
      "answer": "B"
    },
    {
      "id": "T7-Q07",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which dedicated CKD trials demonstrated renal protection with SGLT2 inhibitors?",
      "options": [
        "EMPA‑REG, CANVAS, DECLARE",
        "SUSTAIN, LEADER, REWIND",
        "CREDENCE, DAPA‑CKD, EMPA‑KIDNEY",
        "EXSCEL, ELIXA"
      ],
      "answer": "C"
    },
    {
      "id": "T7-Q08",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which heart failure trials demonstrated benefits of SGLT2 inhibitors regardless of diabetes status?",
      "options": [
        "LEADER, SUSTAIN‑6",
        "DAPA‑HF, EMPEROR‑Reduced/Preserved, DELIVER",
        "CREDENCE, DAPA‑CKD",
        "CANVAS, DECLARE"
      ],
      "answer": "B"
    },
    {
      "id": "T7-Q09",
      "type": "standard",
      "difficulty": 3,
      "stem": "Which statement best summarizes the heterogeneity in ‘high CV risk’ across SGLT2 CVOTs?",
      "options": [
        "All trials enrolled identical populations",
        "Only primary prevention cohorts were included",
        "MACE results were uniform across all agents",
        "Definitions varied (established CVD vs multiple risk factors), affecting MACE results"
      ],
      "answer": "D"
    },
    {
      "id": "T7-Q10",
      "type": "standard",
      "difficulty": 3,
      "stem": "Beyond MACE, which consistent benefits were seen across SGLT2 inhibitor CVOTs?",
      "options": [
        "Significant reductions in retinopathy and neuropathy",
        "Marked A1C drops > 2.5%",
        "Reductions in HF hospitalization and renal outcomes",
        "Weight gain benefits"
      ],
      "answer": "C"
    },
    {
      "id": "T7-Q11",
      "type": "standard",
      "difficulty": 3,
      "stem": "Which statement about oral semaglutide (PIONEER‑6) is most accurate?",
      "options": [
        "It reduced MACE similarly to liraglutide",
        "It increased HF hospitalizations",
        "It worsened renal outcomes",
        "It did not demonstrate definitive cardiorenal outcome reduction like some injectable GLP‑1 RAs"
      ],
      "answer": "D"
    },
    {
      "id": "T7-Q12",
      "type": "standard",
      "difficulty": 3,
      "stem": "FLOW trial (2024) focused on which outcome with semaglutide in T2D with CKD?",
      "options": [
        "HF hospitalization only",
        "Retinal outcomes",
        "Hypoglycemia rates",
        "Renal outcomes (CKD progression)"
      ],
      "answer": "D"
    },
    {
      "id": "T7-Q13",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 67‑year‑old with T2D and prior MI asks which SGLT2 trial first showed CV and mortality benefits. Best answer?",
      "options": [
        "DECLARE‑TIMI 58",
        "VERTIS‑CV",
        "CANVAS‑R",
        "EMPA‑REG OUTCOME"
      ],
      "answer": "D"
    },
    {
      "id": "T7-Q14",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 70‑year‑old with T2D and CKD (eGFR 40) asks which trials support renal protection with SGLT2 inhibitors. Best response?",
      "options": [
        "CREDENCE, DAPA‑CKD, EMPA‑KIDNEY",
        "LEADER and REWIND",
        "EXSCEL and ELIXA",
        "PIONEER‑6 only"
      ],
      "answer": "A"
    },
    {
      "id": "T7-Q15",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 72‑year‑old with HF (LVEF 35%) asks which agents lower HF hospitalization risk regardless of diabetes. Best answer?",
      "options": [
        "Dapagliflozin or empagliflozin (based on DAPA‑HF/EMPEROR)",
        "Liraglutide",
        "Sitagliptin",
        "Acarbose"
      ],
      "answer": "A"
    },
    {
      "id": "T7-Q16",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 64‑year‑old with multiple CV risk factors but no established CVD asks if GLP‑1 RAs reduce MACE. Best counseling?",
      "options": [
        "Strong MACE reduction proven in risk‑factor‑only cohorts",
        "Benefit is clearest in established CVD; evidence in risk‑factor‑only patients is less certain",
        "No benefit in any population",
        "Only DPP‑4 inhibitors reduce MACE"
      ],
      "answer": "B"
    },
    {
      "id": "T7-Q17",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 69‑year‑old with ASCVD and CKD asks whether dapagliflozin reduced MACE in DECLARE‑TIMI 58. Best answer?",
      "options": [
        "DECLARE showed the largest MACE reduction among SGLT2 CVOTs",
        "DECLARE worsened renal outcomes",
        "DECLARE did not show significant MACE reduction, but showed HF/renal benefits",
        "DECLARE increased HF events"
      ],
      "answer": "C"
    },
    {
      "id": "T7-Q18",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 62‑year‑old with T2D and prior stroke asks which GLP‑1 RA trial supports MACE reduction. Best answer?",
      "options": [
        "ELIXA (lixisenatide)",
        "EXSCEL (exenatide QW)",
        "REWIND (dulaglutide) and SUSTAIN‑6 (semaglutide)",
        "PIONEER‑6 (oral semaglutide)"
      ],
      "answer": "C"
    },
    {
      "id": "T7-Q19",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 71‑year‑old with CKD asks if SGLT2 renal benefits extend to people without diabetes. Best statement?",
      "options": [
        "Only people with diabetes benefit",
        "Trials excluded non‑diabetic CKD",
        "DAPA‑CKD and EMPA‑KIDNEY included many without diabetes and showed similar benefits",
        "Benefits require A1C > 8%"
      ],
      "answer": "C"
    },
    {
      "id": "T7-Q20",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 66‑year‑old with ASCVD asks whether ertugliflozin reduced MACE. Best answer?",
      "options": [
        "VERTIS‑CV did not show significant MACE reduction",
        "VERTIS‑CV showed the largest MACE reduction",
        "No trial exists",
        "Ertugliflozin increased MACE"
      ],
      "answer": "A"
    }
  ],
  "Insulin Therapy Progression": [
    {
      "id": "T8-Q01",
      "type": "standard",
      "difficulty": 1,
      "stem": "When adding insulin for fasting hyperglycemia, which initial regimen is recommended?",
      "options": [
        "Once‑daily basal insulin (NPH or long‑acting analogue)",
        "Immediate full basal‑bolus",
        "Premixed insulin only",
        "Rapid‑acting insulin only"
      ],
      "answer": "A"
    },
    {
      "id": "T8-Q02",
      "type": "standard",
      "difficulty": 1,
      "stem": "Long‑acting insulin analogues vs NPH insulin are associated with:",
      "options": [
        "Lower risk of symptomatic and nocturnal hypoglycemia",
        "Higher risk of hypoglycemia",
        "No differences",
        "Increased weight loss"
      ],
      "answer": "A"
    },
    {
      "id": "T8-Q03",
      "type": "standard",
      "difficulty": 1,
      "stem": "Compared with glargine U‑100, insulin degludec is associated with:",
      "options": [
        "Higher hypoglycemia",
        "No difference",
        "Greater weight gain",
        "Lower rates of overall, symptomatic, nocturnal, and severe hypoglycemia"
      ],
      "answer": "D"
    },
    {
      "id": "T8-Q04",
      "type": "standard",
      "difficulty": 1,
      "stem": "When mealtime control is needed after basal insulin, the recommended approach is to:",
      "options": [
        "Switch to NPH only",
        "Add all three mealtime doses immediately",
        "Stop basal insulin",
        "Add stepwise bolus at the largest meal first"
      ],
      "answer": "D"
    },
    {
      "id": "T8-Q05",
      "type": "standard",
      "difficulty": 2,
      "stem": "After starting basal insulin, which non‑insulin agents should generally be continued or initiated?",
      "options": [
        "Incretins and/or SGLT2 inhibitors",
        "Sulfonylureas and meglitinides",
        "Acarbose only",
        "No other agents"
      ],
      "answer": "A"
    },
    {
      "id": "T8-Q06",
      "type": "standard",
      "difficulty": 2,
      "stem": "Once bolus insulin is introduced, which class should generally be discontinued to reduce hypoglycemia risk?",
      "options": [
        "Insulin secretagogues (sulfonylureas, meglitinides)",
        "Metformin",
        "SGLT2 inhibitors",
        "GLP‑1 RAs"
      ],
      "answer": "A"
    },
    {
      "id": "T8-Q07",
      "type": "standard",
      "difficulty": 2,
      "stem": "Rapid‑acting insulin analogues compared with regular insulin in T2D are associated with:",
      "options": [
        "Higher hypoglycemia consistently",
        "No difference in any study",
        "Inability to control postprandial glucose",
        "Lower hypoglycemia in some studies"
      ],
      "answer": "D"
    },
    {
      "id": "T8-Q08",
      "type": "standard",
      "difficulty": 2,
      "stem": "Basal insulin should be titrated to which target primarily?",
      "options": [
        "Fasting glucose targets",
        "Postprandial glucose at lunch",
        "Bedtime glucose only",
        "Random glucose only"
      ],
      "answer": "A"
    },
    {
      "id": "T8-Q09",
      "type": "standard",
      "difficulty": 3,
      "stem": "Which statement about glargine U‑300 vs glargine U‑100 is supported by evidence?",
      "options": [
        "U‑300 may lower nocturnal hypoglycemia rates compared with U‑100",
        "U‑300 causes more nocturnal hypoglycemia",
        "They are identical in hypoglycemia risk",
        "U‑300 is contraindicated in T2D"
      ],
      "answer": "A"
    },
    {
      "id": "T8-Q10",
      "type": "standard",
      "difficulty": 3,
      "stem": "Which strategy achieved similar A1C with less hypoglycemia compared to immediate full basal‑bolus?",
      "options": [
        "Premixed BID from the start",
        "Basal insulin only",
        "Stepwise addition of a single mealtime bolus (Basal‑Plus)",
        "Basal switch to NPH"
      ],
      "answer": "C"
    },
    {
      "id": "T8-Q11",
      "type": "standard",
      "difficulty": 3,
      "stem": "In people starting basal insulin, adding which class can reduce insulin dose requirements and weight gain?",
      "options": [
        "GLP‑1 RA",
        "Sulfonylurea",
        "Meglitinide",
        "Acarbose"
      ],
      "answer": "A"
    },
    {
      "id": "T8-Q12",
      "type": "standard",
      "difficulty": 3,
      "stem": "Which basal insulin shows lower hypoglycemia than glargine U‑100 in RCTs of T2D?",
      "options": [
        "NPH",
        "Detemir consistently",
        "Regular insulin",
        "Degludec"
      ],
      "answer": "D"
    },
    {
      "id": "T8-Q13",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 62‑year‑old on metformin needs insulin due to fasting hyperglycemia. Which initiation is preferred?",
      "options": [
        "Start full basal‑bolus immediately",
        "Add once‑daily basal insulin and titrate",
        "Add rapid‑acting insulin only",
        "Switch to premixed only"
      ],
      "answer": "B"
    },
    {
      "id": "T8-Q14",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 70‑year‑old on basal insulin has high post‑dinner glucose. Next best step?",
      "options": [
        "Increase basal indefinitely",
        "Stop all non‑insulin agents",
        "Switch to regular insulin only",
        "Add a mealtime bolus at the largest meal and titrate"
      ],
      "answer": "D"
    },
    {
      "id": "T8-Q15",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 66‑year‑old on basal insulin + sulfonylurea has frequent hypoglycemia after adding a lunch bolus. Best adjustment?",
      "options": [
        "Increase sulfonylurea",
        "Stop basal insulin",
        "Stop the sulfonylurea",
        "Add a second bolus immediately"
      ],
      "answer": "C"
    },
    {
      "id": "T8-Q16",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 58‑year‑old on basal insulin asks about reducing nocturnal hypoglycemia. Which basal switch is supported by evidence?",
      "options": [
        "Switch to NPH",
        "Switch to regular insulin",
        "Increase basal dose",
        "Switch to degludec"
      ],
      "answer": "D"
    },
    {
      "id": "T8-Q17",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 64‑year‑old has A1C 7.9% despite basal insulin + metformin + SGLT2 inhibitor. Fasting glucose is at target but post‑prandials are high. Next step?",
      "options": [
        "Increase basal insulin only",
        "Stop metformin",
        "Add stepwise mealtime bolus insulin",
        "Add sulfonylurea"
      ],
      "answer": "C"
    },
    {
      "id": "T8-Q18",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 72‑year‑old on basal insulin experiences nocturnal hypoglycemia. Which basal option has lower nocturnal hypoglycemia risk than glargine U‑100?",
      "options": [
        "NPH",
        "Glargine U‑300 or degludec",
        "Detemir is always superior",
        "Regular insulin"
      ],
      "answer": "B"
    },
    {
      "id": "T8-Q19",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 55‑year‑old with obesity prefers fewer injections and weight control when intensifying beyond basal insulin. Best option?",
      "options": [
        "Add full basal‑bolus immediately",
        "Switch to premixed only",
        "Add a GLP‑1 RA instead of multiple boluses initially",
        "Add sulfonylurea"
      ],
      "answer": "C"
    },
    {
      "id": "T8-Q20",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 69‑year‑old asks whether rapid‑acting analogues reduce hypoglycemia compared with regular insulin. Best answer?",
      "options": [
        "Some studies show lower hypoglycemia with analogues",
        "Analogues always increase hypoglycemia",
        "No RCTs compare them",
        "Regular insulin eliminates hypoglycemia"
      ],
      "answer": "A"
    }
  ],
  "Combining Insulin With Other Agents": [
    {
      "id": "T9-Q01",
      "type": "standard",
      "difficulty": 1,
      "stem": "When initiating basal insulin, which non‑insulin agents should generally be continued or started?",
      "options": [
        "Sulfonylurea",
        "Meglitinide",
        "Acarbose",
        "GLP‑1 RA and/or SGLT2 inhibitor"
      ],
      "answer": "D"
    },
    {
      "id": "T9-Q02",
      "type": "standard",
      "difficulty": 1,
      "stem": "Adding non‑insulin agents when starting insulin may have which benefit?",
      "options": [
        "Increased hypoglycemia",
        "No added benefit",
        "Immediate remission",
        "Lower insulin dose requirements and less weight gain"
      ],
      "answer": "D"
    },
    {
      "id": "T9-Q03",
      "type": "standard",
      "difficulty": 1,
      "stem": "Once bolus insulin is added, which medications should usually be discontinued?",
      "options": [
        "Sulfonylureas and meglitinides",
        "Metformin",
        "DPP‑4 inhibitors",
        "SGLT2 inhibitors"
      ],
      "answer": "A"
    },
    {
      "id": "T9-Q04",
      "type": "standard",
      "difficulty": 1,
      "stem": "Why are sulfonylureas usually stopped after adding mealtime insulin?",
      "options": [
        "To increase weight loss",
        "To reduce hypoglycemia risk",
        "They are ineffective with insulin",
        "They are contraindicated in all insulin users"
      ],
      "answer": "B"
    },
    {
      "id": "T9-Q05",
      "type": "standard",
      "difficulty": 2,
      "stem": "Combining basal insulin with which class improves A1C with less hypoglycemia and weight gain than intensifying insulin alone?",
      "options": [
        "Sulfonylurea",
        "Meglitinide",
        "Acarbose",
        "GLP‑1 RA"
      ],
      "answer": "D"
    },
    {
      "id": "T9-Q06",
      "type": "standard",
      "difficulty": 2,
      "stem": "In people on multiple daily injections (MDI), adding which class reduced weight and insulin dose without increasing hypoglycemia?",
      "options": [
        "Sulfonylurea",
        "Meglitinide",
        "SGLT2 inhibitor",
        "Acarbose"
      ],
      "answer": "C"
    },
    {
      "id": "T9-Q07",
      "type": "standard",
      "difficulty": 2,
      "stem": "Combining insulin with metformin compared with insulin alone typically results in:",
      "options": [
        "More hypoglycemia",
        "Worse glycemic control",
        "Less weight gain and hypoglycemia",
        "Immediate discontinuation of insulin"
      ],
      "answer": "C"
    },
    {
      "id": "T9-Q08",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which class should be considered over secretagogues when insulin is intensified due to lower hypoglycemia risk?",
      "options": [
        "Meglitinide",
        "Another sulfonylurea",
        "GLP‑1 RA or SGLT2 inhibitor",
        "Thiazolidinedione"
      ],
      "answer": "C"
    },
    {
      "id": "T9-Q09",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 65‑year‑old on basal insulin + metformin remains above target. Which add‑on is most likely to improve A1C with weight benefit?",
      "options": [
        "Increase basal indefinitely",
        "GLP‑1 RA",
        "Sulfonylurea",
        "Meglitinide"
      ],
      "answer": "B"
    },
    {
      "id": "T9-Q10",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 60‑year‑old on MDI asks about adding an SGLT2 inhibitor. Which outcome is expected based on trials?",
      "options": [
        "No change in metrics",
        "Marked increase in hypoglycemia",
        "Improved glucose, weight loss, lower insulin dose without more hypoglycemia",
        "Universal DKA"
      ],
      "answer": "C"
    },
    {
      "id": "T9-Q11",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 70‑year‑old on basal insulin + sulfonylurea has frequent lows after adding lunch bolus. Best adjustment?",
      "options": [
        "Increase sulfonylurea",
        "Stop basal insulin",
        "Stop sulfonylurea",
        "Add bedtime bolus"
      ],
      "answer": "C"
    },
    {
      "id": "T9-Q12",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 58‑year‑old asks if metformin should be continued after starting basal insulin. Best answer?",
      "options": [
        "No, metformin must be stopped",
        "Metformin causes hypoglycemia with insulin",
        "Yes, continuing metformin may reduce insulin dose and weight gain",
        "Continue only if A1C < 7%"
      ],
      "answer": "C"
    },
    {
      "id": "T9-Q13",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 62‑year‑old on basal insulin and metformin remains above A1C target with post‑dinner highs. Best next step to minimize hypoglycemia and weight gain?",
      "options": [
        "Add sulfonylurea",
        "Add meglitinide",
        "Add GLP‑1 RA",
        "Increase basal only"
      ],
      "answer": "C"
    },
    {
      "id": "T9-Q14",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 59‑year‑old on MDI is obese and asks about adding an oral agent for weight loss and glycemic benefit. Best choice?",
      "options": [
        "Add sulfonylurea",
        "Add SGLT2 inhibitor",
        "Add acarbose",
        "Add meglitinide"
      ],
      "answer": "B"
    },
    {
      "id": "T9-Q15",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 68‑year‑old on basal insulin + GLP‑1 RA has A1C 7.6% with high post‑breakfast glucose. Next step?",
      "options": [
        "Increase basal only",
        "Stop GLP‑1 RA",
        "Add a breakfast bolus insulin dose",
        "Add sulfonylurea"
      ],
      "answer": "C"
    },
    {
      "id": "T9-Q16",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 71‑year‑old on basal insulin reports recurrent afternoon hypoglycemia after adding a lunch bolus while still on glyburide. Best adjustment?",
      "options": [
        "Increase lunch bolus",
        "Add meglitinide",
        "Stop glyburide (a sulfonylurea)",
        "Stop basal insulin"
      ],
      "answer": "C"
    },
    {
      "id": "T9-Q17",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 63‑year‑old on MDI asks whether adding empagliflozin will increase hypoglycemia. Best counseling?",
      "options": [
        "They universally increase hypoglycemia",
        "They are contraindicated with insulin",
        "They offer no glycemic benefit",
        "SGLT2 inhibitors improved control with weight loss and no increased hypoglycemia in trials"
      ],
      "answer": "D"
    },
    {
      "id": "T9-Q18",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 58‑year‑old prefers fewer injections when intensifying beyond basal insulin. Which is a reasonable alternative to multiple boluses?",
      "options": [
        "Add sulfonylurea",
        "Add meglitinide",
        "Only increase basal dose",
        "Add a GLP‑1 RA"
      ],
      "answer": "D"
    },
    {
      "id": "T9-Q19",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 70‑year‑old with obesity on basal insulin + metformin seeks weight loss and lower insulin dose. Which add‑on aligns with evidence?",
      "options": [
        "Sulfonylurea",
        "SGLT2 inhibitor",
        "Meglitinide",
        "TZD"
      ],
      "answer": "B"
    },
    {
      "id": "T9-Q20",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 64‑year‑old on basal‑bolus + sulfonylurea has frequent lows. Guideline‑concordant action?",
      "options": [
        "Discontinue the sulfonylurea",
        "Add another bolus",
        "Increase basal dose",
        "Stop metformin"
      ],
      "answer": "A"
    }
  ],
  "Special Populations and Safety Considerations": [
    {
      "id": "T10-Q01",
      "type": "standard",
      "difficulty": 1,
      "stem": "Safety of incretin agents (GLP‑1 RA/GIP‑GLP‑1) and SGLT2 inhibitors in pregnancy is:",
      "options": [
        "Proven safe in all trimesters",
        "Unknown; avoid or discontinue in pregnancy or if not using reliable contraception",
        "Contraindicated only during breastfeeding",
        "Safe if A1C > 9%"
      ],
      "answer": "B"
    },
    {
      "id": "T10-Q02",
      "type": "standard",
      "difficulty": 1,
      "stem": "Maximum doses of many antihyperglycemic medications are determined by which factor?",
      "options": [
        "Age",
        "Sex",
        "Renal function (eGFR)",
        "Body weight alone"
      ],
      "answer": "C"
    },
    {
      "id": "T10-Q03",
      "type": "standard",
      "difficulty": 1,
      "stem": "All individuals starting insulin should receive education about:",
      "options": [
        "Prevention and management of hypoglycemia",
        "Carbohydrate counting only",
        "Insulin pump use only",
        "Foot care only"
      ],
      "answer": "A"
    },
    {
      "id": "T10-Q04",
      "type": "standard",
      "difficulty": 1,
      "stem": "Long‑term use of metformin has been associated with which deficiency?",
      "options": [
        "Iron deficiency",
        "Vitamin D deficiency",
        "Vitamin B12 deficiency",
        "Folate deficiency"
      ],
      "answer": "C"
    },
    {
      "id": "T10-Q05",
      "type": "standard",
      "difficulty": 2,
      "stem": "Which statement about pancreatitis risk with incretins best reflects evidence cited in the guideline?",
      "options": [
        "Markedly increased risk in all users",
        "No conclusive increased risk found in meta‑analyses",
        "Contraindicated due to pancreatitis risk",
        "Only safe with insulin"
      ],
      "answer": "B"
    },
    {
      "id": "T10-Q06",
      "type": "standard",
      "difficulty": 2,
      "stem": "SGLT2 inhibitors are associated with which uncommon but notable risk in T2D?",
      "options": [
        "Severe bradycardia",
        "Pancreatic cancer",
        "Seizures",
        "Diabetic ketoacidosis (rare)"
      ],
      "answer": "D"
    },
    {
      "id": "T10-Q07",
      "type": "standard",
      "difficulty": 2,
      "stem": "SGLT2 inhibitors have which infection‑related safety signal?",
      "options": [
        "Increased bacterial pneumonia",
        "Increased C. difficile",
        "Higher genital mycotic infections",
        "Increased HIV"
      ],
      "answer": "C"
    },
    {
      "id": "T10-Q08",
      "type": "standard",
      "difficulty": 2,
      "stem": "For a person planning pregnancy, which class should be avoided or discontinued?",
      "options": [
        "Metformin",
        "Basal insulin analogues",
        "GLP‑1 RA and SGLT2 inhibitor",
        "Acarbose"
      ],
      "answer": "C"
    },
    {
      "id": "T10-Q09",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 30‑year‑old with T2D planning pregnancy is on dapagliflozin + semaglutide. Best recommendation?",
      "options": [
        "Continue both until second trimester",
        "Continue SGLT2 inhibitor only",
        "Discontinue both agents due to unknown safety in pregnancy",
        "Stop all therapy"
      ],
      "answer": "C"
    },
    {
      "id": "T10-Q10",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 68‑year‑old on canagliflozin asks about bone health. Which statement reflects trial findings discussed in the guideline?",
      "options": [
        "SGLT2 inhibitors universally increase fracture risk",
        "Bone safety signals have been evaluated with variable findings; overall CV/renal benefits remain",
        "They improve bone density in all users",
        "They are contraindicated if age > 65"
      ],
      "answer": "B"
    },
    {
      "id": "T10-Q11",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 64‑year‑old with a history of pancreatitis asks about GLP‑1 RA risk. Best counseling based on cited evidence?",
      "options": [
        "Meta‑analyses do not show a conclusive increased pancreatitis risk",
        "GLP‑1 RAs are proven to double pancreatitis risk",
        "Only DPP‑4 inhibitors carry risk",
        "GLP‑1 RAs cause pancreatitis in >10%"
      ],
      "answer": "A"
    },
    {
      "id": "T10-Q12",
      "type": "standard",
      "difficulty": 3,
      "stem": "A 58‑year‑old on long‑term metformin presents with neuropathy and macrocytosis. Which lab is most relevant?",
      "options": [
        "Serum ferritin",
        "TSH",
        "Vitamin B12 level",
        "25‑OH Vitamin D"
      ],
      "answer": "C"
    },
    {
      "id": "T10-Q13",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 27‑year‑old with T2D not using reliable contraception is taking semaglutide. Best action?",
      "options": [
        "Continue; it is safe",
        "Switch to SGLT2 inhibitor",
        "Discontinue semaglutide due to unknown safety in pregnancy",
        "Add sulfonylurea"
      ],
      "answer": "C"
    },
    {
      "id": "T10-Q14",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 45‑year‑old on empagliflozin presents with nausea and malaise after low‑carb diet and illness. Glucose is modestly elevated and ketones positive. Which risk does this illustrate?",
      "options": [
        "Severe hypoglycemia from SGLT2",
        "Acute pancreatitis from SGLT2",
        "Thyroid storm",
        "(Euglycemic) diabetic ketoacidosis with SGLT2 inhibitor"
      ],
      "answer": "D"
    },
    {
      "id": "T10-Q15",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 62‑year‑old started on SGLT2 inhibitor reports genital itching. Most likely diagnosis?",
      "options": [
        "Urinary tract carcinoma",
        "Pneumonia",
        "C. difficile colitis",
        "Genital mycotic infection"
      ],
      "answer": "D"
    },
    {
      "id": "T10-Q16",
      "type": "vignette",
      "difficulty": 2,
      "stem": "A 58‑year‑old on metformin for 8 years presents with anemia and paresthesias. Which evaluation is most appropriate?",
      "options": [
        "Check vitamin B12 level",
        "Check serum calcium",
        "Order MRI brain",
        "Stop all diabetes meds"
      ],
      "answer": "A"
    },
    {
      "id": "T10-Q17",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 35‑year‑old with T2D planning to conceive is on liraglutide and ertugliflozin. Most appropriate plan?",
      "options": [
        "Continue both until second trimester",
        "Switch to DPP‑4 inhibitor for pregnancy",
        "Stop both agents and transition to therapies with known pregnancy safety",
        "Only stop ertugliflozin"
      ],
      "answer": "C"
    },
    {
      "id": "T10-Q18",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 70‑year‑old on canagliflozin asks about infections. Best counseling?",
      "options": [
        "Severe UTIs are inevitable",
        "There are no infection risks",
        "Antifungal prophylaxis is mandatory",
        "Genital mycotic infections are more common; counsel on hygiene and early treatment"
      ],
      "answer": "D"
    },
    {
      "id": "T10-Q19",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 52‑year‑old with prior pancreatitis asks if GLP‑1 RA is absolutely contraindicated. Best response?",
      "options": [
        "Absolutely contraindicated",
        "Safer to use DPP‑4 inhibitor only",
        "No monitoring is needed",
        "Evidence does not show conclusive increased risk; discuss risks/benefits and monitor"
      ],
      "answer": "D"
    },
    {
      "id": "T10-Q20",
      "type": "vignette",
      "difficulty": 3,
      "stem": "A 29‑year‑old pregnant patient with T2D is on metformin. She asks about adding an SGLT2 inhibitor for kidney protection. Best answer?",
      "options": [
        "Safe to start now",
        "Only start in third trimester",
        "Start GLP‑1 RA instead",
        "Avoid SGLT2 inhibitors in pregnancy due to unknown safety"
      ],
      "answer": "D"
    }
  ]
}